FGFR2 and gastric cancer: In the ongoing clinical trial NCT01795768 (a proof of concept Phase II Trial for AZD4547) as discussed above, the authors identified that all of the FGFR2 amplified gastric cancers that responded to therapy had elevated levels of circulating cell free plasma DNA [90].